-+ 0.00%
-+ 0.00%
-+ 0.00%
Bausch + Lomb Reports Phase 2 Results For BL1332; Primary Endpoint Missed, Exploratory Analyses Show Pain Relief And Faster Corneal Healing
Share
Listen to the news
  • Both BL1332 doses demonstrated numerically greater pain relief than vehicle across all primary, secondary and exploratory pain analyses; the primary endpoint at 24 hours was not met
  • Exploratory analyses showed more patients achieved complete pain relief following surgery and faster corneal epithelium recovery when treated with BL1332
  • Results support discussions with FDA regarding future development, including potential Phase 3 planning

Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from a Phase 2 study evaluating BL1332, a first-in-class topical TRPV1 antagonist, in patients experiencing pain following photorefractive keratectomy (PRK) surgery.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending